Comments

UroGen Pharma Stock Guidance

URGNNASDAQ
Logo brought to you by Benzinga Data
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$9.46
0.000.00%
Q4 2024 Earnings in 7 days from now on Mon Mar 10th, before the market open
Conference call scheduled in 7 days at 10:00 AM Click to view the webcast
UroGen Pharma (URGN) ForecastNewsEarningsUroGen Pharma (URGN) Options

Guidance

DividendsAnalyst RatingsInsider TradesShort Interest

UroGen Pharma Stock Guidance | NASDAQ:URGN | Benzinga

UroGen Pharma issues guidance on future EPS and revenue, giving investors insight into how much the company expects to earn in upcoming periods.

Data brought to you by Benzinga APIs

FAQ

Q

What is the most recent guidance for UroGen Pharma (URGN)?

A

There have been no specific sales or earnings guidance reported for UroGen Pharma in recent months.

Browse guidance and forecast on all stocks.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved